Edward E. Diehl, Ph.D.

I have more than 25 years of experience evaluating and developing life science technologies. I hold a B.S. in Biology from the Pennsylvania State University and a Ph.D. in Physiology and Biophysics from the University of Iowa. I completed a National Cancer Institute sponsored fellowship in Biochemistry and Molecular Biology at the Mayo Clinic and a fellowship in Pharmacology at Duke University. I was later appointed to two faculty positions – Assistant Professor of Natural and Health Sciences at Barry University and Research Assistant Professor at the Northwestern University School of Medicine. I was subsequently hired as a Senior Scientist in the Diagnostic Division of Abbott Laboratories where my work contributed to the validation and launch of seven cancer diagnostic tests on three instrument platforms. I moved on to entrepreneurial roles at several startups and a CRO where I participated in R&D, investment, licensing, and business and intellectual property development efforts. I was a member of the Technology Evaluation Committee for the Office of Technology Development at the Medical College of Wisconsin and subsequently hired as their Intellectual Property Marketing Manager. In 2008, I launched the Diehl Group which has now become Pathway Biotechnology.

Daniel F. Walsh, Jr.

For more than 25 years, I have advised hundreds of companies in the medical technology industry including: Johnson & Johnson, Pfizer, Phillips, PTV Sciences, Baxter, GSK, and Schering AG. My focus is on the successful development, scale-up, launch and delivery of breakthrough medical technologies that both benefit patients and manage the exploding cost of the healthcare system. These technologies span a number of biomedical disciplines including cardiovascular, neurology, endocrinology, orthopedics, MIS & general surgery, gastrointestinal (GI), dental, ophthalmology, hematology, women’s health, in vitro diagnostics, and telehealth/ehealth.